Marksans Pharma arm gets UK drug regulator's authorisation for oral solution to treat high blood sugar levels

Shares of Marksans Pharma Ltd gained on Friday, May 30, after the company said its subsidiary secured marketing authorisation from the UK regulator for its oral solution used for treating high blood sugar levels.

The company in a stock exchange filing said The UK Medicines and Healthcare Products Regulatory Agency (UKMHRA) issued market authorisation for the former's subsidiary Relonchem Ltd's Metformin Hydrochloride oral solution in the 500 mg/5 ml strength.

The approval marks an important milestone for Marksans Pharma as it expands its presence in the anti-diabetic therapeutic segment in the UK market, according to the company.

Metformin Hydrochloride Oral Solution is used in the treatment of type 2 diabetes and is an essential medication for patients requiring oral liquid dosage forms.

Earlier this month, Relonchem received marketing authorisation from the UK regulator for Sennosides 7.5 mg tablets, a medication used to treat constipation, according to the US government's MedlinePlus website.

Also in May, Relonchem secured the regulator's approval for Gabapentin Oral Solution, 50 mg/ml, which is prescribed to manage nerve pain and epilepsy.

In March, Marksans Pharma's manufacturing facility in Verna, Goa, received approval from Australia's Therapeutic Goods Administration (TGA), further expanding the company's regulatory clearances across global markets.

Shares of Marksans Pharma gained as much as 1.78% to hit an intraday high of ₹265 apiece on the BSE on May 30. However, the stock pared some of the early gains to trade 0.44% higher at ₹261.5 apiece at 10:12 AM.

Also Read: Suzlon Energy shares jump 13% after profit, deliveries jump in Q4; Check new price target